JP2014523913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523913A5 JP2014523913A5 JP2014521732A JP2014521732A JP2014523913A5 JP 2014523913 A5 JP2014523913 A5 JP 2014523913A5 JP 2014521732 A JP2014521732 A JP 2014521732A JP 2014521732 A JP2014521732 A JP 2014521732A JP 2014523913 A5 JP2014523913 A5 JP 2014523913A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cancer cell
- cell
- cancer cells
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 100
- 238000000034 method Methods 0.000 claims description 71
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 201000011510 cancer Diseases 0.000 claims description 67
- 229920001184 polypeptide Polymers 0.000 claims description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 37
- 230000000087 stabilizing effect Effects 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 20
- 238000011394 anticancer treatment Methods 0.000 claims description 14
- 239000013603 viral vector Substances 0.000 claims description 14
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 claims description 11
- 210000004899 c-terminal region Anatomy 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 238000000315 cryotherapy Methods 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 3
- 206010065305 Cancer in remission Diseases 0.000 claims description 2
- 206010038111 Recurrent cancer Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 238000007792 addition Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509891P | 2011-07-20 | 2011-07-20 | |
| US61/509,891 | 2011-07-20 | ||
| PCT/US2012/047198 WO2013012922A1 (en) | 2011-07-20 | 2012-07-18 | Adenovirus e1a fragments for use in anti-cancer therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523913A JP2014523913A (ja) | 2014-09-18 |
| JP2014523913A5 true JP2014523913A5 (cg-RX-API-DMAC7.html) | 2015-09-10 |
Family
ID=47556185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014521732A Pending JP2014523913A (ja) | 2011-07-20 | 2012-07-18 | 抗がん治療法で用いるためのアデノウイルスｅ１ａ断片 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8716014B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2734219B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014523913A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013012922A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017223385A1 (en) * | 2016-06-22 | 2017-12-28 | The Children's Hospital Of Philadelphia | Protein vii fragments and methods of use thereof for the treatment of inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| CA2250222A1 (en) | 1996-03-20 | 1997-09-25 | Mien-Chie Hung | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| US7883888B2 (en) * | 2000-04-05 | 2011-02-08 | The Research Foundation —The State University of New York | Peptides selectively lethal to malignant and transformed mammalian cells |
| US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
| KR100972618B1 (ko) | 2007-10-19 | 2010-07-27 | 국립암센터 | 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법 |
-
2012
- 2012-07-18 US US13/552,407 patent/US8716014B2/en not_active Expired - Fee Related
- 2012-07-18 WO PCT/US2012/047198 patent/WO2013012922A1/en not_active Ceased
- 2012-07-18 EP EP12814909.3A patent/EP2734219B1/en not_active Not-in-force
- 2012-07-18 JP JP2014521732A patent/JP2014523913A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Connexin and pannexin channels in cancer | |
| Liu et al. | An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation | |
| Ortiz et al. | New gene therapy strategies for cancer treatment: a review of recent patents | |
| Chen et al. | PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1 | |
| Wang et al. | Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy | |
| CN108135977B (zh) | 包含同时表达IL-12和shVEGF的腺病毒的抗肿瘤免疫力增强组合物 | |
| Dai et al. | Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1 | |
| Maes et al. | Roles of connexins and pannexins in digestive homeostasis | |
| Liao et al. | Yes-associated protein 1 promotes papillary thyroid cancer cell proliferation by activating the ERK/MAPK signaling pathway | |
| Lojkin et al. | Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer | |
| Wang et al. | A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer | |
| JP2015516370A5 (cg-RX-API-DMAC7.html) | ||
| JP2020516293A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression | |
| Kim et al. | Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation | |
| Liu et al. | Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma | |
| Weng et al. | ZBTB20 is involved in liver regeneration after partial hepatectomy in mouse | |
| Zhou et al. | MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone‐mediated autophagy | |
| Shang et al. | ZnPPIX inhibits peritoneal metastasis of gastric cancer via its antiangiogenic activity | |
| Xu et al. | Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma | |
| JP2014523913A5 (cg-RX-API-DMAC7.html) | ||
| Tada et al. | A potential therapeutic strategy for malignant mesothelioma with gene medicine | |
| Gao et al. | Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA | |
| Zhang et al. | Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV)-mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer | |
| Guo et al. | Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model |